Skip to content
The Policy VaultThe Policy Vault

rivaroxaban oral suspensionMedica

Venous thromboembolism prophylaxis in acutely ill medical patients

Initial criteria

  • Patient is age ≥ 18 years
  • If rivaroxaban oral suspension is being requested, patient is unable to have Xarelto tablets appropriately administered

Approval duration

60 days